<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220480</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-04-3434-JZ-CTIL</org_study_id>
    <nct_id>NCT00220480</nct_id>
  </id_info>
  <brief_title>A Naturalistic Study of the Efficacy and Safety of Escitalopram in Treatment Resistant Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicenter study is to evaluate the efficacy of escitalopram
      in treatment resistant depression (TRD), assessed by 2 consecutive failed antidepressant
      treatments from different classes. The last treatment received is a 6 week prospective trial
      with venlafaxine.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2005</start_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MADRS</measure>
    <time_frame>8 to 10 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>escitalopram</intervention_name>
    <description>10 to 30 mg / day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Any patient who meets all of the following criteria is eligible for inclusion in the
        Prospective phase I of the study:

          1. The patient is able to read and understand the patient information sheet.

          2. Prior to any screening procedures, the patient must have signed the informed consent
             form. No study-related procedures may be performed before the patient has signed the
             form.

          3. The patient is an in- or outpatient, male or female.

          4. The patient is between 18 and 65 years of age.

          5. The patient suffers from a diagnosis of recurrent Major Depressive Disorder (current
             episode assessed with the MINI), moderate or severe, according to DSM-IV-TR criteria
             (classification code = 296.3x).

          6. The patient has a total score of 22 or higher on the MADRS.

          7. The patient has been treated for the current episode with an antidepressant (other
             than escitalopram or venlafaxine) prescribed continuously at the optimal dose (see
             table Appendix 1) for at least the 4 weeks preceding selection (AD1).

          8. The investigator considers switching treatment to venlafaxine (AD2), prescribing it at
             its optimal dose, defined by the study protocol.

        Exclusion Criteria:

        Any patient who meets one or more of the following criteria cannot be included in the
        screening phase of the study:

          1. The patient has previously participated in this study.

          2. Results from blood sampling at selection show for the antidepressant prescribed (AD1),
             that plasma concentration is below the expected threshold according to time of last
             intake.

          3. The patient has taken another antidepressant in combination to the antidepressant to
             which he/she is considered as non-responder (AD1).

          4. The patient has one or more of the following conditions:

               1. Any current psychiatric disorder established as the principal diagnosis other
                  than Major depressive episode as defined in the DSM-IV-TR (assessed with the
                  MINI).

               2. Any Substance disorder (except nicotine and caffeine) within the previous 6
                  months as defined in the DSM-IV-TR.

               3. Any severe personality disorder according to investigator clinical judgement,
                  that might compromise the study.

          5. The patient uses disallowed recent or concomitant medication within the specified time
             periods:

               1. oral antipsychotic drugs within 2 months and depot antipsychotic preparations
                  within the past 6 months.

               2. ECT within the past 6 months.

               3. lithium, carbamazepine, valproate or valpromide within the past month.

               4. any benzodiazepines at a dose higher than 10 mg diazepam or equivalent, within
                  the last week.

               5. any non-benzodiazepine anxiolytics within the last week.

               6. serotonin agonists within the last week.

               7. any other drug with potential psychotropic effects within the last week.

               8. any drug known to lower blood pressure in the last week.

          6. The patient has been treated with any investigational product within 3 months prior to
             screening.

          7. The patient has been treated during the current episode with escitalopram or
             venlafaxine.

          8. The patient has a history of severe drug allergy or hypersensitivity, or known
             hypersensitivity to escitalopram or venlafaxine.

          9. The patient started (or will start) formal psychotherapy in the month preceding
             inclusion.

         10. The patient has a previous history of convulsive disorder other than a single
             childhood febrile seizure.

         11. The patient presents evidence of urinary retention or glaucoma.

         12. The patient has a serious illness and/or serious sequelae thereof, including liver or
             renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine,
             neurological, infectious, neoplastic, or metabolic disturbance.

         13. The patient has, in the opinion of the investigator, on the basis of a physical
             examination, medical history and vital signs, a comorbid conditions(s) that would
             render inclusion in the study unsafe.

         14. The patient takes medication that, in the opinion of the investigator, could interfere
             with the assessments of safety, tolerability, or efficacy.

         15. The patient, in the opinion of the investigator, is unlikely to comply with the
             clinical study protocol or is unsuitable for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Zohar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Fostick, MA</last_name>
    <phone>+972-3-5357805</phone>
    <email>Leah.Fostick@sheba.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Fostick, MA</last_name>
      <phone>+972-3-5357805</phone>
      <email>Leah.Fostick@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ness Ziona Mental Health Center</name>
      <address>
        <city>Ness Ziona</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Fostick, MA</last_name>
      <phone>+972-3-5357805</phone>
      <email>Leah.Fostick@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gehah Mental Health Center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Fostick, MA</last_name>
      <phone>+972-3-5357805</phone>
      <email>Leah.Fostick@health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Fostick, MA</last_name>
      <phone>+972-3-5357805</phone>
      <email>Leah.Fostick@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>February 7, 2010</last_update_submitted>
  <last_update_submitted_qc>February 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Joseph Zohar</name_title>
    <organization>Chaim Sheba Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

